Amedeo Smart

Free Medical Literature Service




  Free Subscription


3 Clin Infect Dis
2 Clin Microbiol Rev
1 Infect Immun
1 J Gen Virol
1 J Infect
1 J Infect Dis
3 J Virol
1 Lancet
3 MMWR Morb Mortal Wkly Rep
2 N Engl J Med
1 Nat Immunol
1 Nat Med
1 Pediatr Infect Dis J
1 Pediatrics
1 PLoS Comput Biol
10 PLoS One
2 Proc Natl Acad Sci U S A
3 Science
14 Vaccine
1 Virology


  1. GIANSERRA L, Dona MG, Giuliani E, Stingone C, et al
    High seroconversion rate after vaccination with mRNA BNT162b2 vaccine against SARS-CoV-2 among people with HIV - but HIV viremia matters?
    AIDS. 2022;36:1319-1320.
    >> Share

  2. WOLDEMESKEL BA, Karaba AH, Garliss CC, Beck EJ, et al
    Decay of coronavirus disease 2019 mRNA vaccine-induced immunity in people with HIV.
    AIDS. 2022;36:1315-1317.
    >> Share

  3. CRUM NF, Ahmad A
    Immunity against measles in people with HIV: the need for more research and surveillance.
    AIDS. 2022;36:1305-1306.
    >> Share


  4. HORNE EMF, Hulme WJ, Keogh RH, Palmer TM, et al
    Waning effectiveness of BNT162b2 and ChAdOx1 covid-19 vaccines over six months since second dose: OpenSAFELY cohort study using linked electronic health records.
    BMJ. 2022;378:e071249.
    >> Share

  5. POPLE D, Monk EJM, Evans S, Foulkes S, et al
    Burden of SARS-CoV-2 infection in healthcare workers during second wave in England and impact of vaccines: prospective multicentre cohort study (SIREN) and mathematical model.
    BMJ. 2022;378:e070379.
    >> Share

    Rapid covid-19 vaccination for health workers.
    BMJ. 2022;378:o1674.
    >> Share

  7. HULME WJ, Williamson EJ, Green ACA, Bhaskaran K, et al
    Comparative effectiveness of ChAdOx1 versus BNT162b2 covid-19 vaccines in health and social care workers in England: cohort study using OpenSAFELY.
    BMJ. 2022;378:e068946.
    >> Share

    Clin Infect Dis

  8. SAHNI LC, Naioti EA, Olson SM, Campbell AP, et al
    Sustained within-season vaccine effectiveness against influenza-associated hospitalization in children: Evidence from the New Vaccine Surveillance Network, 2015-2016 through 2019-2020.
    Clin Infect Dis. 2022 Jul 22. pii: 6648556. doi: 10.1093.
    >> Share

  9. KLING K, Domingo C, Bogdan C, Duffy S, et al
    Duration of protection after vaccination against yellow fever - systematic review and meta-analysis.
    Clin Infect Dis. 2022 Jul 20. pii: 6646957. doi: 10.1093.
    >> Share

  10. HATFIELD KM, Baggs J, Wolford H, Fang M, et al
    Effectiveness of COVID-19 vaccination against SARS-CoV-2 Infection among Residents of US Nursing Homes, Before and During the Delta variant Predominance, December 2020 - November 2021.
    Clin Infect Dis. 2022 Jul 20. pii: 6646955. doi: 10.1093.
    >> Share

    Clin Microbiol Rev

  11. ZHOU H, Mohlenberg M, Thakor JC, Tuli HS, et al
    Sensitivity to Vaccines, Therapeutic Antibodies, and Viral Entry Inhibitors and Advances To Counter the SARS-CoV-2 Omicron Variant.
    Clin Microbiol Rev. 2022 Jun 6:e0001422. doi: 10.1128/cmr.00014.
    >> Share

  12. CHOY RKM, Bourgeois AL, Ockenhouse CF, Walker RI, et al
    Controlled Human Infection Models To Accelerate Vaccine Development.
    Clin Microbiol Rev. 2022 Jul 6:e0000821. doi: 10.1128/cmr.00008.
    >> Share

    Infect Immun

  13. SCHMIDT LK, Orne CE, Shaffer TL, Wilson SM, et al
    Development of Melioidosis Subunit Vaccines Using an Enzymatically Inactive Burkholderia pseudomallei AhpC.
    Infect Immun. 2022 Jul 11:e0022222. doi: 10.1128/iai.00222.
    >> Share

    J Gen Virol

  14. SEESEN M, Jearanaiwitayakul T, Limthongkul J, Sunintaboon P, et al
    Mice immunized with trimethyl chitosan nanoparticles containing DENV-2 envelope domain III elicit neutralizing antibodies with undetectable antibody-dependent enhancement activity.
    J Gen Virol. 2022;103.
    >> Share

    J Infect

  15. HAGIYA H, Hikita T, Habu T, Asada M, et al
    Poor vaccine responsiveness towards third-dose mRNA vaccine of COVID-19 in Japanese older people.
    J Infect. 2022 Jul 11. pii: S0163-4453(22)00413.
    >> Share

    J Infect Dis

  16. MAHANT A, Guerguis S, Blevins TP, Cheshenko N, et al
    Herpes Simplex Virus Glycoprotein D Antibodies Fail to Elicit Antibody-Dependent Cell-Mediated Cytotoxicity: Implications for Future Vaccines.
    J Infect Dis. 2022 Jul 14. pii: 6644507. doi: 10.1093.
    >> Share

    J Virol

  17. PUSNIK J, Konig J, Mai K, Richter E, et al
    Persistent Maintenance of Intermediate Memory B Cells Following SARS-CoV-2 Infection and Vaccination Recall Response.
    J Virol. 2022 Jul 12:e0076022. doi: 10.1128/jvi.00760.
    >> Share

  18. CHAPARIAN RR, Harding AT, Hamele CE, Riebe K, et al
    A Virion-Based Combination Vaccine Protects against Influenza and SARS-CoV-2 Disease in Mice.
    J Virol. 2022 Jul 12:e0068922. doi: 10.1128/jvi.00689.
    >> Share

  19. RAMIREZ-MEDINA E, Vuono E, Silva E, Rai A, et al
    Evaluation of the Deletion of MGF110-5L-6L on Swine Virulence from the Pandemic Strain of African Swine Fever Virus and Use as a DIVA Marker in Vaccine Candidate ASFV-G-DeltaI177L.
    J Virol. 2022 Jul 11:e0059722. doi: 10.1128/jvi.00597.
    >> Share


  20. KIM YE, Huh K, Park YJ, Peck KR, et al
    Association Between Vaccination and Acute Myocardial Infarction and Ischemic Stroke After COVID-19 Infection.
    JAMA. 2022 Jul 22. pii: 2794753. doi: 10.1001/jama.2022.12992.
    >> Share

    Mix-and-Match COVID-19 Boosters After Inactivated Virus Vaccine.
    JAMA. 2022;328:234.
    >> Share


    Perilous two-tier COVID-19 global vaccine roll-out.
    Lancet. 2022 Jul 11. pii: S0140-6736(22)01284.
    >> Share

    MMWR Morb Mortal Wkly Rep

  23. HAUSE AM, Baggs J, Marquez P, Abara WE, et al
    Safety Monitoring of COVID-19 mRNA Vaccine First Booster Doses Among Persons Aged >/=12 Years with Presumed Immunocompromise Status - United States, January 12, 2022-March 28, 2022.
    MMWR Morb Mortal Wkly Rep. 2022;71:899-903.
    >> Share

  24. MERCED-MORALES A, Daly P, Abd Elal AI, Ajayi N, et al
    Influenza Activity and Composition of the 2022-23 Influenza Vaccine - United States, 2021-22 Season.
    MMWR Morb Mortal Wkly Rep. 2022;71:913-919.
    >> Share

  25. LINK-GELLES R, Levy ME, Gaglani M, Irving SA, et al
    Effectiveness of 2, 3, and 4 COVID-19 mRNA Vaccine Doses Among Immunocompetent Adults During Periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 Sublineages Predominated - VISION Network, 10 States, December 2021-June 2022.
    MMWR Morb Mortal Wkly Rep. 2022;71:931-939.
    >> Share

    N Engl J Med

  26. TAN SHX, Cook AR, Heng D, Ong B, et al
    Effectiveness of BNT162b2 Vaccine against Omicron in Children 5 to 11 Years of Age.
    N Engl J Med. 2022 Jul 20. doi: 10.1056/NEJMoa2203209.
    >> Share

  27. SCHONBORN L, Seck SE, Thiele T, Warkentin TE, et al
    SARS-CoV-2 Infection in Patients with a History of VITT.
    N Engl J Med. 2022 Jun 27. doi: 10.1056/NEJMc2206601.
    >> Share

    Nat Immunol

  28. QI H, Liu B, Wang X, Zhang L, et al
    The humoral response and antibodies against SARS-CoV-2 infection.
    Nat Immunol. 2022;23:1008-1020.
    >> Share

    Nat Med

  29. LUONG NGUYEN LB, Ghosn J, Durier C, Tachot C, et al
    A prospective national cohort evaluating ring MVA vaccination as post-exposure prophylaxis for monkeypox.
    Nat Med. 2022 Jul 13. pii: 10.1038/d41591-022-00077.
    >> Share

    Pediatr Infect Dis J

  30. ARTETA-ACOSTA C, Villena Martinez R, Santolaya de Pablo ME
    Sequelae at Hospital Discharge in 61 Children With Invasive Meningococcal Disease, Chile, 2009-2019.
    Pediatr Infect Dis J. 2022;41:607-613.
    >> Share


  31. SHAH MD, Szilagyi PG, Shetgiri R, Delgado JR, et al
    Trends in Parents' Confidence in Childhood Vaccines During the COVID-19 Pandemic.
    Pediatrics. 2022 Jul 14. pii: 188519. doi: 10.1542/peds.2022-057855.
    >> Share

    PLoS Comput Biol

  32. HILL EM, Prosser NS, Ferguson E, Kaler J, et al
    Modelling livestock infectious disease control policy under differing social perspectives on vaccination behaviour.
    PLoS Comput Biol. 2022;18:e1010235.
    >> Share

    PLoS One

  33. ABD EL FADEEL MR, Soliman EM, Allam AM, ElKersh MF, et al
    Efficacy and durability of bovine virus diarrhea (BVD) virus killed vaccine adjuvanted with monolaurin.
    PLoS One. 2022;17:e0269031.
    >> Share

  34. FATIMA S, Zafar A, Afzal H, Ejaz T, et al
    COVID-19 infection among vaccinated and unvaccinated: Does it make any difference?
    PLoS One. 2022;17:e0270485.
    >> Share

  35. ABUHAMMAD S, Khabour OF, Alzoubi KH, Hamaideh S, et al
    The public's attitude to and acceptance of periodic doses of the COVID-19 vaccine: A survey from Jordan.
    PLoS One. 2022;17:e0271625.
    >> Share

  36. ZHANG A, Li D, Song C, Jing H, et al
    Evaluation of different combination of pam2CSK4, poly (I:C) and imiquimod enhance immune responses to H9N2 avian influenza antigen in dendritic cells and duck.
    PLoS One. 2022;17:e0271746.
    >> Share

  37. JUNGE M, Li S, Samaranayake S, Zalesak M, et al
    Safe reopening of university campuses is possible with COVID-19 vaccination.
    PLoS One. 2022;17:e0270106.
    >> Share

  38. HANSON CK, Liu K
    Think about your friends and family: The disparate impacts of relationship-centered messages on privacy concerns, protective health behavior, and vaccination against Covid-19.
    PLoS One. 2022;17:e0270279.
    >> Share

  39. SIEGERS KE, van Herwaarden AE, de Waard JH, Del Nogal B, et al
    The metabolic hormone adiponectin affects the correlation between nutritional status and pneumococcal vaccine response in vulnerable indigenous children.
    PLoS One. 2022;17:e0270736.
    >> Share

  40. HERMAN B, Wong MC, Viwattanakulvanid P
    Vaccination status, favipiravir, and micronutrient supplementation roles in post-COVID symptoms: A longitudinal study.
    PLoS One. 2022;17:e0271385.
    >> Share

  41. LIU B, Zhang M, Li X, Liu L, et al
    Influence of epidemic situation on COVID-19 vaccination between urban and rural residents in China-Vietnam border area: A cross-sectional survey.
    PLoS One. 2022;17:e0270345.
    >> Share

  42. GUJJULA KR, Gong J, Segundo B, Ntaimo L, et al
    COVID-19 vaccination policies under uncertain transmission characteristics using stochastic programming.
    PLoS One. 2022;17:e0270524.
    >> Share

    Proc Natl Acad Sci U S A

  43. RABB N, Bowers J, Glick D, Wilson KH, et al
    The influence of social norms varies with "others" groups: Evidence from COVID-19 vaccination intentions.
    Proc Natl Acad Sci U S A. 2022;119:e2118770119.
    >> Share

  44. TOWNSEND JP, Hassler HB, Sah P, Galvani AP, et al
    The durability of natural infection and vaccine-induced immunity against future infection by SARS-CoV-2.
    Proc Natl Acad Sci U S A. 2022;119:e2204336119.
    >> Share


  45. CHEN R, Guo X, Zhu A
    Vaccinate to combat COVID-19 in China.
    Science. 2022;377:271.
    >> Share

  46. BOWEN JE, Addetia A, Dang HV, Stewart C, et al
    Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines.
    Science. 2022 Jul 19:eabq0203. doi: 10.1126/science.abq0203.
    >> Share

  47. REYNOLDS CJ, Pade C, Gibbons JM, Otter AD, et al
    Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure.
    Science. 2022 Jun 14:eabq1841. doi: 10.1126/science.abq1841.
    >> Share


  48. NIESSEN FA, Knol MJ, Hahne SJM, Bonten MJM, et al
    Vaccine effectiveness against COVID-19 related hospital admission in the Netherlands: A test-negative case-control study.
    Vaccine. 2022 Jun 8. pii: S0264-410X(22)00758.
    >> Share

  49. DUGORD C, Franc C
    Trajectories and individual determinants of repeated seasonal flu vaccination use over the long term using data from the French E3N cohort.
    Vaccine. 2022 Jul 18. pii: S0264-410X(22)00855.
    >> Share

  50. WALTON S, Cortina-Borja M, Dezateux C, Griffiths LJ, et al
    Linking cohort data and Welsh routine health records to investigate children at risk of delayed primary vaccination.
    Vaccine. 2022 Jul 13. pii: S0264-410X(22)00849.
    >> Share

  51. IMANISHI Y, Kinoshita T, Sakamoto M, Ichimiya M, et al
    Importance of human papillomavirus vaccination leaflets focusing on the safety profile targeted pediatricians in Japan.
    Vaccine. 2022 Jul 13. pii: S0264-410X(22)00861.
    >> Share

  52. ORTQVIST AK, Dahlqwist E, Magnus MC, Ljung R, et al
    COVID-19 vaccination in pregnant women in Sweden and Norway.
    Vaccine. 2022 Jul 12. pii: S0264-410X(22)00859.
    >> Share

  53. BARRALL AL, Hoff NA, Nkamba DM, Musene K, et al
    Hesitancy to receive the novel coronavirus vaccine and potential influences on vaccination among a cohort of healthcare workers in the Democratic Republic of the Congo.
    Vaccine. 2022 Jul 1. pii: S0264-410X(22)00842.
    >> Share

  54. CUFFEL A, Maylin S, Le Buanec H, Delaugerre C, et al
    Humoral and cellular responses to SARS-CoV-2 BNT162b2 vaccination in allogeneic hematopoietic stem cell transplantation recipients.
    Vaccine. 2022 Jul 11. pii: S0264-410X(22)00857.
    >> Share

  55. PADRON-REGALADO E, Medina-Rivero E
    Perspectives for licensing vaccines in Mexico.
    Vaccine. 2022 Jul 11. pii: S0264-410X(22)00854.
    >> Share

  56. HATFALUDI T, Rezaee MS, Liebhart D, Bilic I, et al
    Experimental reproduction of histomonosis caused by Histomonas meleagridis genotype 2 in turkeys can be prevented by oral vaccination of day-old birds with a monoxenic genotype 1 vaccine candidate.
    Vaccine. 2022 Jul 11. pii: S0264-410X(22)00851.
    >> Share

  57. SHINKAI M, Sonoyama T, Kamitani A, Shibata RY, et al
    Immunogenicity and safety of booster dose of S-268019-b or BNT162b2 in Japanese participants: An interim report of phase 2/3, randomized, observer-blinded, noninferiority study.
    Vaccine. 2022;40:4328-4333.
    >> Share

  58. ATWELL JE, Lutz CS, Sparrow EG, Feikin DR, et al
    Biological factors that may impair transplacental transfer of RSV antibodies: Implications for maternal immunization policy and research priorities for low- and middle-income countries.
    Vaccine. 2022 Jun 17. pii: S0264-410X(22)00783.
    >> Share

  59. SADOFF J, Le Gars M, Brandenburg B, Cardenas V, et al
    Durable antibody responses elicited by 1 dose of Ad26.COV2.S and substantial increase after boosting: 2 randomized clinical trials.
    Vaccine. 2022;40:4403-4411.
    >> Share

  60. COWLING BJ, Wong IOL, Shiu EYC, Lai AYT, et al
    Strength and durability of antibody responses to BNT162b2 and CoronaVac.
    Vaccine. 2022;40:4312-4317.
    >> Share

  61. DE BROUWER L, David D, Espitia Ballestas M, Sloots A, et al
    Prevalidation of the cAMP-PTx reporter assay for quantitative assessment of pertussis toxin activity.
    Vaccine. 2022;40:4513-4521.
    >> Share


  62. KONG D, Wen Z, Su H, Ge J, et al
    Corrigendum to "Newcastle disease virus vectored Nipah encephalitis vaccines induce B and T cell responses in mice and long-lasting neutralizing antibodies in pigs" [Virology 432 (2012) 327-335].
    Virology. 2022;573:176-177.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016